Engineered Lactococcus lactis secreting a glucagon-like peptide-1-inducing protein P9 for amelioration of obesity in mice.

This study investigated the anti-obesity potential of Lactococcus lactis engineered to constitutively secrete P9 (Amuc_1631), a protein from Akkermansia muciniphila. Our findings show that the engineered strain L. lactis P11P9 effectively secretes P9 and significantly increases GLP-1 production in NCI-H716 enteroendocrine cells, with a 2.65-fold rise compared to controls. In high-fat diet (HFD)-induced obese mice, oral administration of L. lactis P11P9 resulted in reduced weight gain, decreased food intake, and attenuation of adipocyte hypertrophy. ELISA analysis of serum samples indicated that L. lactis P11P9 treatment elevated circulating GLP-1 levels. RT-qPCR analysis further revealed increased expression of GLP-1 synthesis-related genes (e.g., GCG and PCSK1) in intestinal tissues. In addition, transcription of thermogenesis-associated genes such as UCP1 and PGC-1α was upregulated in adipose tissue. Taken together, this study suggests that engineered L. lactis P11P9 helps reduce obesity by increasing GLP-1 secretion and stimulating thermogenesis, providing a promising strategy for obesity treatment.

Supplementary information: The online version contains supplementary material available at 10.1007/s13205-025-04465-5.